 1. Cohort A: After a non-myeloablative conditioning regimen, 5 patients will receive one bulk infusion of T cells. T cells will be expanded ex vivo from autologous tumor infiltrating lymphocytes TIL. In vivo persistence of the infused cells will be supported by administration of IL-2, a T cell survival factor. 